Advancing excellence in laboratory medicine for better healthcare worldwide

Education in the Use of Biomarkers in Diabetes (C-EUBD)


NamePositionCountryTermTime in Office
E. EnglishChairUK1st2021 04 - 2023 12
E. Van der HagenMemberNL1st2022 01 - 2024 12
A. SatoMemberJP2nd2022 01 - 2024 12
J. SkrhaMemberCZ1st2022 01 - 2024 12
E. KilpatrickMemberUK1st2022 05 -2024 12
D. SacksConsultantUS
C. SiebelderConsultantNL

Terms of reference

  1. To maintain and further develop the network of reference laboratories for the measurement of HbA1c (through collaboration with C-TLM)
  2. To work in partnership with WHO and IDF to continue to promote the reporting of HbA1c in line with the consensus statement
  3. To work in partnership with WHO and IDF to facilitate the development and implementation of international guidelines for the use of HbA1c in the diagnosis of diabetes
  4. To work with IFCC Corporate Members to develop a consensus position on the information to be included in the Instructions for Use (IFU) as it relates to the clinical use of HbA1c methods
  5. Develop quality targets for the measurement of HbA1c and other biomarkers, and on the basis of these targets, and in conjunction with professional bodies, advise on the use of biomarkers for monitoring, diagnosis and screening of diabetes and glucose intolerance.
  6. To work with WHO and TF-POCT to recommend best practice in the use of POCT methods for the measurement of HbA1c
  7. To evaluate the clinical value of emerging biomarkers (e.g. glycated albumin) for the management of patients with diabetes and to establish whether there is a case for method harmonisation of effective new biomarkers
  8. To evaluate the emerging importance of post translational modification derived products (PTMDPs), and especially Advanced Glycation End-Products (AGEs), and work with Professional bodies on the best way of developing these for use in diabetes.
  9. To monitor the literature and advise on best practice in relation to laboratory aspects of diabetes.

List of Corresponding Members, nominated by National Societies

NameIFCC Member Society
D. AslanTurkish Biochemical Society (TBS)
W. Cheneke GebisaEthiopian Medical Laboratory Association (EMLA)
E. SchleicherDeutche Gesellschaft fur Klinische Chemie und Laboratoriumsmedizin e.V. (DGKL)
A. MoscaItalian Society of Clinical Chemistry and Clinical Molecular Biology (SIBioC)
Iiris SalonenFinnish Society of Clinical Chemistry (SKKY)
A. CojLithuanian Society of Laboratory Medicine
E.Rojano-RodriguezMexican Association of Clinical Laboratory Sciences (CMCLabC)
R. Kumar DubeyNepalese Association for Clinical Chemistry (NACC)
B. Kumar YadavNepalese Association for Laboratory Science (NAMLS)
B. OkesinaAssociation of Clinical Chemists Nigeria (ACCN)
R. NandaAssociation of Medical Biochemists of India (AMBI)
M. BanerjeeAssociation of Clinical Biochemists of India (ACBI)
P. GillerySociété Francaise de Biologie Clinique (SFBC)
L. Figueroa MontesAssociacion Medica Peruana de Patologia Clinica (AMPPC)

List of Corresponding Members, nominated by Corporate Members

S. BaraldiA. Menarini Diagnostics
M. BermanAbbott
P. CampbellLumiraDx
H. BoeSebia
R. MolinaroSiemens Healthcare

Committee Chair's contact

Prof. Emma ENGLISH

Associate Professor
School of Health Sciences,
University of East Anglia
Norwick Research Park,
Norwich, Norfolk

Website developed by Insoft